Video

VIDEO: Panoply of new agents, complete remission rates mark ‘special day’ in myeloma

Ruben Niesvizky, MD, director of the Multiple Myeloma Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York, discusses the “privilege” of caring for patients with myeloma in an era of therapeutic milestones.

“We’re starting to talk about complete remission in a much deeper context,” he said. “The ability to achieve complete remission to a minimal residual disease-negative state has allowed patients to live longer and have better quality of life.”

Niesvizky discusses three-agent combinations of proteasome inhibitors, immunomodulators and corticosteroids and the “revolution” in agents available for relapsed and refractory disease, detailing therapeutic scenarios and their respective responses.

He also outlines the distinct treatment phases involved in today’s treatment paradigms, highlighting the “major impact” seen using a combination of carfilzomib (Kyprolis, Onyx Pharmaceuticals), lenalidomide (Revlimid; Celgene) and dexamethasone for induction.

He goes on to highlight the progress in using immune-based strategies, including monoclonal antibodies either alone or in combination with other therapies, and details populations in which the approaches show promise.

Ruben Niesvizky, MD, director of the Multiple Myeloma Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York, discusses the “privilege” of caring for patients with myeloma in an era of therapeutic milestones.

“We’re starting to talk about complete remission in a much deeper context,” he said. “The ability to achieve complete remission to a minimal residual disease-negative state has allowed patients to live longer and have better quality of life.”

Niesvizky discusses three-agent combinations of proteasome inhibitors, immunomodulators and corticosteroids and the “revolution” in agents available for relapsed and refractory disease, detailing therapeutic scenarios and their respective responses.

He also outlines the distinct treatment phases involved in today’s treatment paradigms, highlighting the “major impact” seen using a combination of carfilzomib (Kyprolis, Onyx Pharmaceuticals), lenalidomide (Revlimid; Celgene) and dexamethasone for induction.

He goes on to highlight the progress in using immune-based strategies, including monoclonal antibodies either alone or in combination with other therapies, and details populations in which the approaches show promise.

    See more from At Issue: Multiple Myeloma